

13 April 2022

Botanix Pharmaceuticals to announce upcoming BTX 1801 Data Presentations at European Congress for Clinical Microbiology and Infectious Diseases

Key highlights

- Botanix will be presenting data for its clinical-stage asset BTX 1801 at the upcoming 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2022) on 23–26 April 2022
- ECCMID 2022 will take place in Lisbon, Portugal and can be watched live at <https://www.eccmid.org/>
- BTX 1801 data will be presented at the ECCMID session 5a: *Mechanisms of action, new compounds, preclinical data & pharmacology of antibacterial agents* and includes:
 - *The Antimicrobial profile of BTX 1801: a new synthetic cannabidiol active against Gram-positive bacteria associated with serious infections* (Abstract number: 00129) and
 - *Bactericidal activity of BTX 1801: a synthetic cannabidiol with potent activity versus Staphylococcus aureus* (Abstract number: 00145)
- The presentations will be hosted by lead authors Professor Geoffrey Coombs and Ms Angela Kavanagh

Philadelphia PA and Phoenix AZ, 13 April 2022: Clinical dermatology company, Botanix Pharmaceuticals Limited (ASX: BOT, “Botanix” or “the Company”), is pleased to announce upcoming presentations of data related to its antimicrobial synthetic cannabidiol program BTX 1801, at the upcoming 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2022).

ECCMID 2022 will take place in Lisbon, Portugal on 23–26 April 2022 as a hybrid event. In addition to attendance on-site, the event will be live-streamed at <https://www.eccmid.org/>.

ECCMID brings together leading experts from across the globe in the areas of infectious diseases, infection control and clinical microbiology to present and discuss most recent clinical results. Two presentations of BTX 1801 data (Abstract number: 00129 and Abstract number: 00145) will take place during ECCMID Session 5a. *Mechanisms of action, new compounds, preclinical data & pharmacology of antibacterial agents*.

Details of the upcoming two presentations of BTX 1801 data from the Abstract numbers: 00129 and 00145 include the following.

The Antimicrobial profile of BTX-1801: a new synthetic cannabidiol active against Gram-positive bacteria associated with serious infections (Abstract number: 00129) will be presented by lead author Professor Geoffrey Coombs PhD, FASM, RCPA FFSc, FISAC, Chair of Public Health, College of Science, Health, Engineering and Education, Murdoch University.

The abstract presents results of an evaluation of BTX 1801 activity against a broad panel of gram-positive aerobic bacteria with clinically important resistance phenotypes. Analyses of the panel

testing results support the Company's Nature Research peer-reviewed paper in January 2021 of, *Communications Biology*¹ which demonstrated that BTX 1801 was a potent inhibitor of *Staphylococcus* strains, vancomycin-intermediate strains, and enterococci including vancomycin-resistant strains.

Professor Geoffrey Coombs, the lead author of abstract 00129 remarked: *"Staphylococcus aureus is a major cause of bacteremia, particularly in patients with central venous catheters (CVCs) who are admitted to intensive care units or undergoing high risk surgical procedures or hemodialysis. BTX 1801 is a promising agent that is being developed to prevent serious gram-positive infections in patients who are intranasal S aureus carriers at increased risk of bacteremia, due to hemodialysis vascular access with central venous catheters".*

The Bactericidal activity of BTX 1801: a synthetic cannabidiol with potent activity versus *Staphylococcus aureus* (Abstract number: 00145) will be presented by Angela Kavanagh, at the Centre for Superbug Solution, Institute for Molecular Bioscience, The University of Queensland. The abstract supports the Company's published² synthetic cannabidiol time kill data and its interaction with MRSA bacteria membrane, suggesting potential modes of action for cannabidiol.

Ms Kavanagh remarked: *"The novel mechanism of BTX 1801 bactericidal action includes membrane disruption and inhibition of nucleic acid, phospholipid and protein synthesis and is consistent with its low propensity for Gram positive agents like S aureus, to develop resistance to BTX 1801."*

Botanix President and Executive Chair Vince Ippolito said: *"The data to be presented at the upcoming ECCMID 2022 conference suggests the significant potential of BTX 1801 to prevent S. aureus bloodstream infections associated with considerable morbidity, mortality, and cost in haemodialysis patients who use Central Venous Catheters (CVC)."*

"We look forward to sharing the compelling BTX 1801 data with leading infectious disease experts at the upcoming EDDMID 2022 conference."

Release authorised by

Vince Ippolito

President and Executive Chairman

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology focused company based in Perth (Australia) and Philadelphia (USA) committed to the development of pharmaceutical products that are underpinned by science and supported by well-controlled randomised clinical trials. The Company has two separate development platforms - dermatology and antimicrobial products - both of which

¹ "The antimicrobial potential of cannabidiol" available via open access at <https://www.nature.com/articles/s42003-020-01530-y>

² ibid

currently leverage the unique anti-inflammatory, immune modulating and antimicrobial properties of cannabinoids, particularly synthetic cannabidiol or CBD. Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases, which it utilises in its existing development programs and is being explored with a view to being utilized in a number of other product opportunities. To learn more please visit: <http://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Corporate Communications

Botanix Pharmaceuticals

P: +61 8 6555 2945

investors@botanixpharma.com

Investor enquiries

Hannah Howlett

WE Communications

P: +61 450 648 064

hhowlett@we-worldwide.com

Media enquiries

Haley Chartres

H^CK

P: +61 423 139 163

haley@hck.digital

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.